Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Pharmaceutical
Michel Pettigrew, the most senior officer at privately-held drugmaker Ferring, is to retire at the end of the year, the Switzerland-based company has announced. 31 October 2018
Pharmaceutical
For the era of personalized therapies to truly arrive, industry observers often express the view that pharma will have to improve its understanding not just of biology and medicines, but also of certain new technologies that are likely to determine companies’ future way of working. 30 October 2018
Pharmaceutical
At the annual congress of the European Society of Medical Oncology (ESMO) this week, AstraZeneca’s Susan Galbraith told The Pharma Letter the firm was “very proud to have had back to back presidential symposia” at the event, “last year with PACIFIC and FLAURA and this year with SOLO-1." 25 October 2018
Pharmaceutical
Kerry Garcia and Nyasha Gardner, UK-based immigration specialists at law firm Stevens & Bolton, provide an Expert View what the recently published Migration Advisory Committee (MAC) report on immigration means for businesses in the life sciences sector. 25 October 2018
Pharmaceutical
Russia’s arrival as a major player in the digitalization of healthcare was abundantly clear at a Moscow event held to celebrate and stimulate advances in the sector. 25 October 2018
Pharmaceutical
Serbian drugmaker Galenika plans to build a new plant in Russia’s St Petersburg that will specialize on the production of its branded drugs, according to the company, reports The Pharma Letter’s local correspondent. 24 October 2018
Biotechnology
US biotech Celgene has appointed Dr Alise Reicin as president, global clinical development, reporting to Mark Alles, chairman and chief executive, effective November 1, 2018. 24 October 2018
Biotechnology
Simon Jose, a Brit who has spent more than 30 years in pharma, is to become chief commercial officer of Idorsia, the research-based spin-out from Actelion following the latter’s acquisition by Johnson & Johnson. 23 October 2018
Pharmaceutical
Welcome again to The Pharma Letter’s new column, RARE: Illuminating Orphan Diseases. October 1 was International Gaucher Day, a day to raise awareness of a lysosomal storage disorder that annually affects one in every 60,000 individuals in the general population and one in every 1,000 individuals in the Ashkenazi Jewish population.1 We look at the current status of Gaucher disease diagnosis and treatment, as well what pharma need to do to advance the options available to this population. 23 October 2018
Pharmaceutical
While PARP blocker rivals AstraZeneca and Tesaro chase the prize of a first-line ovarian cancer indication, Clovis Oncology is highlighting what it sees as promising prostate cancer data at this year’s ESMO congress. 19 October 2018
Pharmaceutical
Something like 20,000 conference delegates are gathered in Munich for the start of what promises to be another important meeting of the European Society of Medical Oncology. 19 October 2018
Biotechnology
Intrathecal catheterization is a highly effective delivery method for drugs targeting neurological diseases, writes Brad Gien, head of surgery, North America, Envigo, in an Expert View piece. 17 October 2018
Biotechnology
Swedish firm Medivir has announced that Uli Hacksell will replace Christine Lind as chief executive, with immediate effect, just 18 months after she took up the position. 16 October 2018
Pharmaceutical
Jesper Brandgaard (pictured above) is to retire after 20 years with Danish pharma major Novo Nordisk, vacating the role of executive vice president, Biopharm and Legal Affairs. 15 October 2018
Pharmaceutical
Previous scandals and improvements in standards and transparency mean that the conversations and exchanges of information that take place between pharmaceutical companies and healthcare practitioners (HCPs) are now closely regulated in many countries. 12 October 2018
Biotechnology
Initial public offerings (IPOs) are often seen as attractive by business owners in the life sciences or biotech field, writes Alan Wovsaniker, a partner with Lowenstein Sandler, in an Expert View column on the topic. 11 October 2018
Pharmaceutical
The China subsidiary of French pharma major Sanofi on October 8 signed a strategic agreement with the Association of County Hospital President, a government -backed organization aiming to improve clinical practices in China’s rural areas, reports The Pharma Letter’s local correspondent Wang Fangqing. 11 October 2018
Pharmaceutical
Incoming Pfizer chief executive Albert Bourla is to stamp his mark firmly on the company’s leadership, as the firm announced a new executive team ready to clock on from the commencement of his tenure next year. 10 October 2018
Pharmaceutical
Ireland-headquartered generic and OTC drugmaker Perrigo, which recently said it was restructuring into two separate units, has announced the appointment of Murray Kessler as president, chief executive and member of the board of directors, effective immediately. 10 October 2018
Pharmaceutical
The Russian government plans to provide access to imported drugs that have not undergone clinical trials within Russia, according to recent statements by some senior officials of the Russian Ministry of Health. 10 October 2018
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze